Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending July 18, 2016. The document serves as a transaction notification regarding a specific securities transaction involving a Person Discharging Managerial Responsibilities (PDMR).
Key Financial Metrics
The filing does not provide consolidated financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It is a regulatory disclosure of a single transaction event.
| Metric | Value |
|---|---|
| Transaction Type | Acquisition of Ordinary Shares (Dividend Re-investment) |
| Instrument | Ordinary Shares of 25 pence each (ISIN: GB0009252882) |
| Transaction Price | £16.6781 |
| Volume | 112.161 shares |
| Transaction Date | July 14, 2016 |
| Exchange | London Stock Exchange (XLON) |
Material Changes
The filing does not report material changes to the company's financial position or operations compared to prior periods. It solely documents the acquisition of shares by the CFO following the re-investment of dividends paid on July 14, 2016.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a standard compliance notification under Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934.
Key Facts for Investor Verification
- Transaction Nature: The acquisition was not a market purchase but a result of dividend re-investment.
- Individual Involved: Mr. S. Dingemans, Chief Financial Officer (CFO).
- Share Count: The volume of 112.161 shares represents a fractional share acquisition typical of dividend reinvestment plans.
- Price Point: The transaction occurred at £16.6781 per share on the London Stock Exchange.